A cikin 'yan kwanan nan, Shanghai Epiprobe Biotechnology Co., Ltd. (ana nufin "Epiprobe") ya sanar da cewa ya kammala kusan RMB 100 miliyan a cikin kudade na Series B, wanda babban birnin masana'antu, dandamali na zuba jari na gwamnati da kuma kamfanin da aka jera Yiyi Shares (SZ) suka saka hannun jari. : 001206).
An kafa shi a cikin 2018, Epiprobe, a matsayin mai ɗaukaka kuma majagaba na farkon gwajin cutar kansa, babban kamfani ne na fasaha wanda ke mai da hankali kan gano ƙwayoyin ƙwayoyin cuta na kansa da ingantattun masana'antar magunguna.Gina kan ƙwararrun ƙwararrun ƙwararrun epigenetics da tarin ilimin kimiyya mai zurfi, Epiprobe ya bincika fagen gano cutar kansa, yana ba da hangen nesa na "nisantar da kowa daga cutar kansa," da himma ga gano wuri, gano wuri da wuri da maganin cutar kansa, ta haka inganta rayuwa. yawan masu fama da cutar kansa don inganta lafiyar jama'a.
Bayan haƙa na tsawon shekaru 20, ƙungiyar Epiprobe da kanta ta gano jerin nau'ikan ciwon daji Aligned General Methylated Epiprobes (TAGMe), waɗanda ke duniya a cikin cututtukan daji daban-daban, don haka haɓaka filin aikace-aikacen.
Game da fasahar ganowa, ana ɗaukar pyrosequencing a al'ada a matsayin "ma'auni na zinariya" don gano methylation, wanda duk da haka ya dogara da jujjuyawar bisulfite, amma yana nuna gazawar kamar ingantaccen juzu'i mara kyau, lalata DNA mai sauƙi, manyan buƙatu ga masu aiki, da kuma dogara ga kayan aiki masu mahimmanci.Waɗannan ƙarancin suna iyakance aikace-aikacen sa.Epiprobe, ta hanyar samar da ci gaban fasaha, da kansa ya haɓaka fasahar gano methylation mai ƙima - Me-qPCR ba tare da jiyya na bisulfite ba, wanda ke rage farashin da haɓaka kwanciyar hankali da aikin asibiti, yana mai sauƙin ganowa da sauƙi.
Epiprobe, yana mai da hankali kan manyan alamomin pan-cancer na kamfanin da hanyoyin gano methylation, ya yi amfani da haƙƙin mallaka na cikin gida da na duniya sama da 50, kuma ya sami izini don kafa ƙaƙƙarfan mai riƙe haƙƙin mallaka.
A halin yanzu, Epiprobe ya yi aiki kafada da kafada da fiye da 40 manyan asibitoci a kasar Sin, ciki har da asibitin Zhongshan, International Peace Maternity da Child Health Hospital, da Changhai Asibitin da dai sauransu, kuma ya aiwatar da m samfurin tsarin a cikin mata mata masu fama da cutar kansa (ciki har da ciwon mahaifa, ciwon daji na endometrial). , Urothelial cancer (ciki har da ciwon mafitsara, ciwon urethra, renal pelvis cancer), huhu cancer, thyroid cancer, hematological cancer da sauran cancers.An aiwatar da ingantaccen makafi sau biyu a cikin samfuran asibiti 70,000 tare da nau'ikan ciwon daji guda 25.
Daga cikin samfuran, don samfuran gano cutar kansar mata masu haifuwa, an aiwatar da ingancin makafi biyu a cikin samfuran asibiti sama da 40,000, kuma an buga jerin sakamakon bincike a cikin shahararrun mujallun ilimi na duniya kamar Binciken Ciwon daji, Clinical da Magungunan Fassara, da Ana aiwatar da gwaje-gwajen asibiti da yawa na manyan-tsalle masu yawa.Yayin da R&D ke ci gaba kuma albarkatun suna ƙaruwa koyaushe, bututun samfuran kamfanin yana ƙaruwa akai-akai.
Madam Hua Lin, Shugabar Kamfanin Epiprobe ta lura cewa: “Babban abin alfahari ne mu sami karɓuwa da kuma tallafa mana daga manyan manyan masana'antu.Epiprobe yana da alaƙa da tarin tarin ilimi, fasaha na musamman, da ingantaccen bincike na asibiti, wanda ya sami amincewar ɓangarorin da yawa.A cikin shekaru hudu da suka gabata, ƙungiyar da ayyukan kamfanin sun ƙara haɓaka.A cikin kwanaki masu zuwa, ba za mu yi ƙoƙari mu gayyato abokan tarayya masu ra'ayi iri ɗaya don ba da haɗin kai da aiki tare, ta yadda za a ci gaba da haɓaka R&D da aiwatar da aikace-aikacen rajista, gami da samar da likitoci da marasa lafiya mafi kyawun sabis na gwajin cutar kansa samfurori."
Lokacin aikawa: Afrilu-11-2022